Top 5 Stocks to Buy Now
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free TLM Stock Alerts

Talisman Metals (TLM) Competitors

Compare

TLM vs. IXI, SBTX, APTA, FAB, and RLM

Should you buy Talisman Metals stock or one of its competitors? MarketBeat compares Talisman Metals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Talisman Metals include IXICO (IXI), SkinBioTherapeutics (SBTX), Aptamer Group (APTA), Fusion Antibodies (FAB), and Realm Therapeutics (RLM). These companies are all part of the "biotechnology" industry.

How does Talisman Metals compare to IXICO?

IXICO (LON:IXI) and Talisman Metals (LON:TLM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Talisman Metals has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Talisman Metals' return on equity.

Company Net Margins Return on Equity Return on Assets
IXICO-24.98% -16.18% -10.40%
Talisman Metals N/A -32.71%3.70%

Talisman Metals has lower revenue, but higher earnings than IXICO. IXICO is trading at a lower price-to-earnings ratio than Talisman Metals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IXICO£7.28M2.50-£3.58M-£1.95N/A
Talisman MetalsN/AN/A-£1.35M-£1.32N/A

IXICO has a beta of 0.129, indicating that its share price is 87% less volatile than the broader market. Comparatively, Talisman Metals has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

In the previous week, IXICO had 1 more articles in the media than Talisman Metals. MarketBeat recorded 1 mentions for IXICO and 0 mentions for Talisman Metals. IXICO's average media sentiment score of 1.60 beat Talisman Metals' score of 0.00 indicating that IXICO is being referred to more favorably in the media.

Company Overall Sentiment
IXICO Very Positive
Talisman Metals Neutral

13.0% of IXICO shares are owned by institutional investors. Comparatively, 1.4% of Talisman Metals shares are owned by institutional investors. 7.2% of IXICO shares are owned by company insiders. Comparatively, 95.2% of Talisman Metals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

IXICO and Talisman Metals tied by winning 6 of the 12 factors compared between the two stocks.

How does Talisman Metals compare to SkinBioTherapeutics?

Talisman Metals (LON:TLM) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

1.4% of Talisman Metals shares are owned by institutional investors. Comparatively, 3.0% of SkinBioTherapeutics shares are owned by institutional investors. 95.2% of Talisman Metals shares are owned by company insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Talisman Metals has higher earnings, but lower revenue than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Talisman Metals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Talisman MetalsN/AN/A-£1.35M-£1.32N/A
SkinBioTherapeutics£4.64M6.33-£3.71M-£0.31N/A

In the previous week, Talisman Metals' average media sentiment score of 0.00 equaled SkinBioTherapeutics'average media sentiment score.

Company Overall Sentiment
Talisman Metals Neutral
SkinBioTherapeutics Neutral

Talisman Metals has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. SkinBioTherapeutics' return on equity of -5.25% beat Talisman Metals' return on equity.

Company Net Margins Return on Equity Return on Assets
Talisman MetalsN/A -32.71% 3.70%
SkinBioTherapeutics -8.73%-5.25%-61.18%

Talisman Metals has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, SkinBioTherapeutics has a beta of 0.121, indicating that its share price is 88% less volatile than the broader market.

Summary

Talisman Metals beats SkinBioTherapeutics on 6 of the 10 factors compared between the two stocks.

How does Talisman Metals compare to Aptamer Group?

Talisman Metals (LON:TLM) and Aptamer Group (LON:APTA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

1.4% of Talisman Metals shares are owned by institutional investors. Comparatively, 3.0% of Aptamer Group shares are owned by institutional investors. 95.2% of Talisman Metals shares are owned by company insiders. Comparatively, 7.3% of Aptamer Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Talisman Metals' average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company Overall Sentiment
Talisman Metals Neutral
Aptamer Group Neutral

Talisman Metals has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.899, indicating that its share price is 10% less volatile than the broader market.

Talisman Metals has higher earnings, but lower revenue than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than Talisman Metals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Talisman MetalsN/AN/A-£1.35M-£1.32N/A
Aptamer Group£1.38M13.39-£14.17M-£0.11N/A

Talisman Metals has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. Talisman Metals' return on equity of -32.71% beat Aptamer Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Talisman MetalsN/A -32.71% 3.70%
Aptamer Group -178.52%-135.35%-44.96%

Summary

Talisman Metals beats Aptamer Group on 6 of the 10 factors compared between the two stocks.

How does Talisman Metals compare to Fusion Antibodies?

Talisman Metals (LON:TLM) and Fusion Antibodies (LON:FAB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Talisman Metals has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Talisman Metals' return on equity of -32.71% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Talisman MetalsN/A -32.71% 3.70%
Fusion Antibodies -91.92%-210.32%-63.78%

1.4% of Talisman Metals shares are held by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are held by institutional investors. 95.2% of Talisman Metals shares are held by company insiders. Comparatively, 5.9% of Fusion Antibodies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Talisman Metals has higher earnings, but lower revenue than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Talisman Metals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Talisman MetalsN/AN/A-£1.35M-£1.32N/A
Fusion Antibodies£1.60M9.44-£4.10M-£1.50N/A

Talisman Metals has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

In the previous week, Fusion Antibodies had 1 more articles in the media than Talisman Metals. MarketBeat recorded 1 mentions for Fusion Antibodies and 0 mentions for Talisman Metals. Talisman Metals' average media sentiment score of 0.00 beat Fusion Antibodies' score of -0.76 indicating that Talisman Metals is being referred to more favorably in the media.

Company Overall Sentiment
Talisman Metals Neutral
Fusion Antibodies Negative

Summary

Talisman Metals beats Fusion Antibodies on 8 of the 12 factors compared between the two stocks.

How does Talisman Metals compare to Realm Therapeutics?

Talisman Metals (LON:TLM) and Realm Therapeutics (LON:RLM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

In the previous week, Talisman Metals' average media sentiment score of 0.00 equaled Realm Therapeutics'average media sentiment score.

Company Overall Sentiment
Talisman Metals Neutral
Realm Therapeutics Neutral

Realm Therapeutics' return on equity of 0.00% beat Talisman Metals' return on equity.

Company Net Margins Return on Equity Return on Assets
Talisman MetalsN/A -32.71% 3.70%
Realm Therapeutics N/A N/A N/A

Realm Therapeutics has higher revenue and earnings than Talisman Metals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Talisman MetalsN/AN/A-£1.35M-£1.32N/A
Realm Therapeutics£501.92K0.00N/A-£17.50N/A

1.4% of Talisman Metals shares are owned by institutional investors. 95.2% of Talisman Metals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Talisman Metals beats Realm Therapeutics on 4 of the 7 factors compared between the two stocks.

Get Talisman Metals News Delivered to You Automatically

Sign up to receive the latest news and ratings for TLM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TLM vs. The Competition

Export
MetricTalisman MetalsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£4.97M£381.56M£6.43B£2.88B
Dividend Yield0.83%3.86%2.68%6.15%
P/E Ratio-6.063.1224.75366.85
Price / SalesN/A6,861.77530.0186,443.43
Price / Cash1.0013.1345.0727.85
Price / BookN/A92.2610.808.01
Net Income-£1.35M-£96.07M£3.57B£5.89B
7 Day Performance5.12%0.88%0.73%0.08%
1 Month Performance6.67%-0.12%1.35%1.15%
1 Year PerformanceN/A54.63%29.31%72.12%

Talisman Metals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TLM
Talisman Metals
N/AN/AN/AN/A£4.97MN/AN/A5
IXI
IXICO
N/AGBX 8.34
-3.6%		N/A-25.3%£18.17M£7.28MN/A89
SBTX
SkinBioTherapeutics
N/AGBX 6.90
+6.2%		N/A-31.7%£17.88M£4.64MN/A11
APTA
Aptamer Group
N/AGBX 0.51
-2.3%		N/A+76.8%£17.73M£1.38MN/A37
FAB
Fusion Antibodies
N/AGBX 12.38
+1.1%		N/A+80.1%£15.48M£1.60MN/A48

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:TLM) was last updated on 6/21/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
A huge SpaceX error just led one stock to 3X move!
SPCE surged roughly 300% in a single week after investors hunting SpaceX exposure piled into the wrong ticker....
InvestPub | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel